Syndax Pharmaceuticals Inc (SNDX)
$19.39-$0.77 (-3.82%) Today
Keith A. Goldan - OfficerKeith A. Goldan - OfficerSyndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 105,914 | $2.12M |
| Option exercise | 6 | 172,250 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
21 Form 4 filings on record, the earliest from Jul 16, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael A. Metzger - Officer | Option exercise | Common Stock | 32,375 | $6.38 | $207K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 32,375 | $24.24 | $785K | |
| Michael A. Metzger - Officer | Option exercise | Stock Option (Right to buy) | 32,375 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Option exercise | Common Stock | 22,515 | $13.82 | $311K | |
| Nicholas A.J. Botwood - Officer | Option exercise | Common Stock | 31,235 | $13.82 | $432K | |
| Nicholas A.J. Botwood - Officer | Open-market sale | Common Stock | 34,280 | $18.00 | $617K | |
| Nicholas A.J. Botwood - Officer | Open-market sale | Common Stock | 31,235 | $18.14 | $567K | |
| Nicholas A.J. Botwood - Officer | Option exercise | Stock options (Right to buy) | 22,515 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Option exercise | Stock options (Right to buy) | 31,235 | $0.00 | - | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 1,177 | $18.99 | $22K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 6,847 | $18.99 | $130K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 17,159 | $21.03 | $361K | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 3,410 | $21.03 | $72K | |
| Michael A. Metzger - Officer | Grant or award | Common Stock | 73,000 | $0.00 | - | |
| Michael A. Metzger - Officer | Grant or award | Common Stock | 144,600 | $0.00 | - | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 7,412 | $20.62 | $153K | |
| Michael A. Metzger - Officer | Grant or award | Stock Options (Right to buy) | 440,000 | $20.43 | $8.99M | |
| Keith A. Goldan - Officer | Other | Common Stock | 1,219 | $8.48 | $10K | |
| Keith A. Goldan - Officer | Grant or award | Common Stock | 21,500 | $0.00 | - | |
| Keith A. Goldan - Officer | Grant or award | Common Stock | 30,750 | $0.00 | - | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 2,082 | $20.62 | $43K | |
| Keith A. Goldan - Officer | Grant or award | Stock Options (Right to buy) | 118,000 | $20.43 | $2.41M | |
 Jennifer Jarrett | Grant or award | Common Stock | 24,000 | $0.00 | - | |
 Martin H. Huber Jr. | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Grant or award | Common Stock | 36,000 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Grant or award | Stock Options (Right to buy) | 144,700 | $20.43 | $2.96M | |
| Dennis Podlesak | Grant or award | Common Stock | 48,000 | $0.00 | - | |
| Aleksandra Rizo | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Keith Katkin | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Pierre Legault | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Keith A. Goldan - Officer | Gift | Common Stock | 1,224 | $0.00 | - | |
| Michael A. Metzger - Officer | Option exercise | Common Stock | 157,307 | $10.90 | $1.71M | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 157,307 | $16.41 | $2.58M | |
| Michael A. Metzger - Officer | Option exercise | Stock options (Right to buy) | 157,307 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $14.19 | $273K | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $15.54 | $298K | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $15.84 | $304K | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 19,200 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 14,400 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 4,800 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 19,200 | $0.00 | - | |
| Keith A. Goldan - Officer | Other | Common Stock | 1,226 | $8.43 | $10K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 7,534 | $9.29 | $70K | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 1,296 | $9.29 | $12K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Syndax Pharmaceuticals Inc (SNDX) had 4 insider filings in the last 90 days, with the most recent on 2026-07-09. The full record for SNDX runs to 21 Form 4 filings, the earliest from 2025-07-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SNDX were filed in the last 90 days.
5 insider sales of SNDX were filed in the last 90 days, totaling $2.12M.
This page tracks SNDX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SNDX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
